High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study will add interleukin-2 (IL-2) to a regimen of post-remission therapy consisting of
high-dose ara-C. Patients with AML in first remission will receive 3 cycles of high-dose
ara-C followed by continuous infusion and bolus interleukin-2 (IL-2). We, the researchers at
the Dana-Farber Cancer Institute, plan to evaluate the immunologic effects of such treatment
in these patients.